Reviewer’s report

Title: Deep cerebral venous thrombosis mimicking influenza-associated acute necrotizing encephalopathy: a case report

Version: 1 Date: 13 Jul 2017

Reviewer: F Schuchardt

Reviewer's report:

Dear Editor, dear authors,

Readability and clarity have improved after revision. I still have some minor remarks. Some of them refer to the use of the English language, given I'm no native-speaker:

1. L68: "Diagnosis is delayed by misdiagnosis ..." I suggest leaving 'by misdiagnosis', as this is redundant.

2. L81: "Her medical and family histories were unremarkable" - as with the use of data, the singular of history sounds more familiar to me - up to the editorial office to decide...

3. L87: please check again on the level of consciousness in the Glasgow Coma Scale scoring: with E=2, hasn't the patient rather been stuporous?

4. L121: "Because drainage through the basal vein of Rosenthal and the superficial cerebral veins was observed, we did not attempt invasive therapeutic procedures, and continued treatment with intravenous glycerol (400 mg per day) and intravenous heparin, followed by warfarin."

   a. The sentence still reads as if you were treating cerebral venous thrombosis (CVT) with osmotic agents. This is only clarified within the discussion, where you refer to the treatment of elevated intracranial pressure (ICP).

   b. Currently there is no statement regarding an actual invasive measurement of ICP. Has this been done, and if so, using which device and which access?
c. I'd divide this sentence, specifying the osmotic treatment was given because of disturbed level of consciousness due to PRESUMED elevated intracranial pressure.

5. L180: "Although both DCVT and ANE are associated with normal white-cell counts in CSF, xanthochromia with a high red-cell count, as observed in our patient, may indicate venous infarction resulting from DCVT, because previous cases of ANE have not shown these results [2]."

From my clinical experience, DCVT is not usually associated with CSF xanthochromia (in the rare case patients with sinus thrombosis receive CSF analysis). Please discuss the mechanism you hold responsible for blood metabolites within CSF due to DCVT. This would require diapedesis of erythrocytes into the CSF. So far a potential causal link is not yet overtly presented.

6. L189: "The current standard methods for making a diagnosis of DCVT are cerebral angiography, MRV and computed tomography angiography. However, these neuroimaging studies are not performed routinely."

This is misleading. When cerebral venous thrombosis is suspected, cerebral imaging is strongly indicated. Does the second sentence within the citation above refer to ANE?

7. Conclusion:

"If bilateral thalamic lesions are identified in patients with influenza infections, immediate diagnosis and treatment of ANE is important. Simultaneously, DCVT should also be kept in mind, because delayed initiation of anticoagulant therapy can lead to unfavorable outcomes."

In my opinion, one of the main messages of this case report is the striking similarity of neuroradiological imaging findings of both the extremely rare ANE and the still rare (but from an epidemiological perspective much more frequent) CVT. Thus, I recommend to further stress the importance of cerebral MR-imaging aiming at increasing clinical certitude that the patients with the imaging findings shown in this report are not affected by CVT. With the current phrasing, those readers, who only read the conclusion, will miss this important teaching point.

8. Figure 1, line 8: "small hyperintensity areas" should be changed to 'hyperintense areas';

Line 12 and second-last line: "abnormal signals" should be changed to 'signal' (singular)
**Level of interest**
Please indicate how interesting you found the manuscript:

An article of importance in its field

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

none

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal